Gilteritinib

Gilteritinib
Clinical data
Trade names	Xospata
AHFS/Drugs.com	Monograph
MedlinePlus	a619003
License data	US DailyMed: Gilteritinib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01EX13 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Identifiers
	IUPAC name 6-Ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide;
CAS Number	1254053-43-4;
PubChem CID	49803313;
DrugBank	DB12141;
ChemSpider	32055842;
UNII	66D92MGC8M;
KEGG	D10709; as salt: D10800;
ChEBI	CHEBI:145372;
CompTox Dashboard (EPA)	DTXSID701027949 ;
Chemical and physical data
Formula	C29H44N8O3
Molar mass	552.724 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCc1nc(C(=O)N)c(Nc2ccc(N3CCC(CC3)N4CCN(C)CC4)c(OC)c2)nc1NC5CCOCC5;
	InChI InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34); Key:GYQYAJJFPNQOOW-UHFFFAOYSA-N;

Gilteritinib, sold under the brand name Xospata, is an anti-cancer drug.